I don’t have live access to current news in this moment, but I can share what’s been reported about Mounjaro (tirzepatide) 2.5 mg/0.5 mL and how to find the latest updates quickly.
Key points to look for in latest news
How to find the latest, reliable sources
If you’d like, I can search for the latest press releases and summarize the top developments with dates and sources. I can also pull only regulatory updates (e.g., new approvals or warnings) if that’s your priority.
For the first time in the UK, obese patients and people who are overweight with weight-related health problems could now have access to Mounjaro, currently used for Type 2 diabetes, to help manage their weight and support weight loss.
www.gov.ukAll strengths of the Mounjaro vial presentation are discontinued but the Mounjaro KwikPen is available in the same strengths.
www.tga.gov.au/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and...
www.prnewswire.comThe Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
investor.lilly.comAPhA Staff New Combination AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE (Voquezna Triple Pak—Phathom Pharmaceuticals, Inc.) Drug class: Amoxicillin is a penicillin-class antibiotic, clarithromycin is a macrolide antibiotic, and vonoprazan is a potassium-competitive acid blocker. Indication: Voquezna Triple Pak is indicated for the treatment of Helicobacter pylori infections in adult patients. Recommended dosage and administration: The recommended dose contained in...
www.pharmacist.comThe US FDA has approved Lilly's Mounjaro as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes.
www.pharmaceutical-technology.comMounjaro KwikPen 2.5mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) by Eli Lilly and Company Limited
www.medicines.org.uk2.1 Dosage • The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. • After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
www.accessdata.fda.gov